Targeted treatment of prostate cancer

Over a half century ago, Charles Huggins demonstrated the response of prostate cancer to androgen deprivation therapy. Subsequently, many discoveries and evolving findings continued to support a research rationale focused on the androgen receptor (AR) as a key target for prostate cancer. More recently, preliminary trials have suggested that other targets could also be useful in the treatment of prostate cancer, and the proposed strategies for treatment have ranged from targeted toxins to immunotherapeutic agents. We provide an overview of some of these approaches, with an emphasis on those that employ prostate specific membrane antigen (PSMA) as a target. J. Cell. Biochem. 102: 571–579, 2007. © 2007 Wiley‐Liss, Inc.

[1]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[2]  M. Pomper,et al.  Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer , 2005, Clinical Cancer Research.

[3]  Matthias D Hofer,et al.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.

[4]  Z. Culig.  Androgen Receptor Cross-talk with Cell Signalling Pathways , 2004, Growth factors.

[5]  W. Fair,et al.  Expression of the prostate-specific membrane antigen. , 1994, Cancer research.

[6]  Dianqing Wu,et al.  Prostate-Specific Membrane Antigen Regulates Angiogenesis by Modulating Integrin Signal Transduction , 2006, Molecular and Cellular Biology.

[7]  Andrew D Ellington,et al.  Aptamer:toxin conjugates that specifically target prostate tumor cells. , 2006, Cancer research.

[8]  N. Callizot,et al.  Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury , 2005, Journal of neurochemistry.

[9]  L. Milas,et al.  Combination of taxanes with radiation: preclinical studies. , 1999, Seminars in radiation oncology.

[10]  P. Kantoff,et al.  Symposium on Androgen Action in Prostate Cancer , 2004, Cancer Research.

[11]  S. Lang,et al.  Prostate cancer stem cells , 2009, The Journal of pathology.

[12]  J. Konvalinka,et al.  Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer , 2006, The EMBO journal.

[13]  Shankar Vallabhajosula,et al.  Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Simon A. Williams,et al.  A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. , 2007, Journal of the National Cancer Institute.

[15]  A. deMoura,et al.  [Cancer of the prostate]. , 1962, Jornal do medico.

[16]  J. Bowie,et al.  A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. , 2003, Molecular biology of the cell.

[17]  P. Hodor,et al.  Interaction between the Androgen Receptor and RNase L Mediates a Cross-talk between the Interferon and Androgen Signaling Pathways* , 2005, Journal of Biological Chemistry.

[18]  J. Folkman,et al.  Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. , 2006, Cancer research.

[19]  S. Vallabhajosula,et al.  Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Rodriguez,et al.  Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen. , 2004, Molecular cancer therapeutics.

[21]  P. Nelson,et al.  Interaction of IGF signaling and the androgen receptor in prostate cancer progression , 2006, Journal of cellular biochemistry.

[22]  Paul J Maddon,et al.  Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen , 2006, Clinical Cancer Research.

[23]  M. Mason,et al.  Cancer of the prostate , 2003 .

[24]  P. Nelson,et al.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.

[25]  G. Jenster,et al.  Evolution of the androgen receptor pathway during progression of prostate cancer. , 2006, Cancer research.

[26]  N. Bander,et al.  Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. , 2003, Cancer research.

[27]  P. Ell,et al.  Safety and efficacy of repeat administration of samarium Sm‐153 lexidronam to patients with metastatic bone pain , 2007, Cancer.

[28]  A. Rajasekaran,et al.  Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix. , 2007, International journal of oncology.

[29]  M. Sadelain,et al.  A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? , 2001, Critical reviews in immunology.

[30]  S. Vallabhajosula,et al.  Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[32]  Prabhjot Kaur,et al.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  A. Meraney,et al.  Recombinant Antibody Candidates for Treatment of Prostate Cancer , 2007 .

[34]  N. Bander,et al.  Constitutive and antibody-induced internalization of prostate-specific membrane antigen. , 1998, Cancer research.

[35]  Shunyou Wang,et al.  Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. S. Coffey,et al.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.

[37]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[38]  A. Vicha,et al.  Expression of glutamate carboxypeptidase II in human brain , 2007, Neuroscience.

[39]  S. Vallabhajosula,et al.  Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Nikitin,et al.  Prostate stem cells and cancer. , 2007, Histology and histopathology.

[41]  D. Tindall,et al.  Molecular regulation of androgen action in prostate cancer , 2006, Journal of cellular biochemistry.

[42]  Michel Sadelain,et al.  Targeted elimination of prostate cancer by genetically directed human T lymphocytes. , 2005, Cancer research.

[43]  Mindy I. Davis,et al.  Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Kozikowski,et al.  Design and Synthesis of a PSMA Inhibitor–Doxorubicin Conjugate for Targeted Prostate Cancer Therapy , 2006, ChemMedChem.

[45]  S. Vallabhajosula,et al.  Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.